Skip to main content
Year archive

4SC AG — 2013 filings

All 39 regulatory filings released by 4SC AG (VSC) in 2013, sourced directly from the official regulator.

39 Filings
2013 Period
2013 filings (39)
Filing Released Lang
Q3 Report 2013
Interim / Quarterly Report 9M 2013
2013-11-09 English
Press Release: 4SC announces improved financial results for the third quarter and first nine months of 2013
Earnings Release 9M 2013
2013-11-07 English
Press Release: 4SC Discovery, AiCuris and CRELUX announce drug discovery collaboration
M&A Activity
2013-11-04 English
Announcement: 4SC to host conference call on 7 November 2013 to present Q3 2013 results
Report Publication Announcement
2013-10-31 English
DGAP-DD: 4SC AG english
Director's Dealing
2013-10-21 English
DGAP-DD: 4SC AG english
Director's Dealing
2013-10-21 English
Press Release: 4SC presents summary of biomarker and patient subgroup analysis of prognostic factors for survival in advanced HCC
Regulatory Filings
2013-09-30 English
Press Release: 4SC Discovery and Panoptes Pharma sign patent transfer agreement for novel compound to treat severe eye diseases
M&A Activity
2013-09-26 English
Press Release: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER trial with resminostat in advanced liver cancer (HCC)
Regulatory Filings
2013-09-13 English
Q2 Report 2013
Interim / Quarterly Report H1 2013
2013-08-20 English
Press Release: 4SC reports second quarter 2013 financial results
Earnings Release H1 2013
2013-08-08 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2012 bis zum 31.12.2012
Audit Report / Information FY 2012
2013-08-06 German
Announcement: 4SC to host conference call on 8 August 2013 to present half year results 2013
Report Publication Announcement
2013-08-01 English
Press Release: 4SC's partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in non-small-cell lung cancer (NSCLC) in Japan
Regulatory Filings
2013-07-25 English
Press Release: 4SC expands patent protection for its epigenetic anti-cancer compound 4SC-202 in the USA, China and Hong Kong
Legal Proceedings Report
2013-07-15 English
Press Release: 4SC announces restructuring associated with recently declared strategic shift
Regulatory Filings
2013-06-20 English
Press Release 4SC AG: UCB to collaborate with CRELUX and 4SC Discovery to meet unmet needs in neurology
Regulatory Filings
2013-06-11 English
Press Release: 4SC gives update on the clinical development of its lead cancer compound resminostat
Earnings Release Q1 2013
2013-05-30 English
Press Release: 4SC's partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in liver cancer in Japan
Regulatory Filings
2013-05-21 English
Konzernabschluss zum Geschäftsjahr vom 01.01.2012 bis zum 31.12.2012
Annual Report FY 2012
2013-05-17 German
Q1 Report 2013
Interim / Quarterly Report Q1 2013
2013-05-16 English
Press Release: 4SC significantly improves operating result in first quarter of 2013 and resolves to focus its development strategy
Earnings Release Q1 2013
2013-05-14 English
Announcement: 4SC to host conference call on 14 May 2013 to present first quarter results of 2013
Report Publication Announcement
2013-05-10 English
Press Release: 4SC to present at two upcoming investor conferences
Regulatory Filings
2013-04-12 English
Annual Financial Statements 2012
Annual Report FY 2012
2013-04-04 English
Annual Financial Statements 2012
Annual Report FY 2012
2013-04-04 German
4 SC AG: Bekanntmachung der Einberufung zur Hauptversammlung am 02.05.2013 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2013-03-25 German
Press Release: 4SC announces financial results for a successful year 2012
Earnings Release FY 2012
2013-03-25 English
Announcement: 4SC to host conference call and webcast on 25 March 2013 to present full year financial results for 2012
Report Publication Announcement
2013-03-18 English
4SC AG: Notice of loss pursuant to section 92 (1) German Stock Corporation Act
Regulatory Filings
2013-03-12 English
4SC AG: Dr Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner
Board/Management Information
2013-03-06 English
Press Release: 4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases
Regulatory Filings
2013-02-26 English
Press Release: 4SC Discovery and BioNTech launch strategic cancer therapy research partnership
M&A Activity
2013-02-20 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2011 bis zum 31.12.2011
Audit Report / Information FY 2011
2013-01-30 German
Report Publication Announcement 2013
Report Publication Announcement
2013-01-14 English
Report Publication Announcement 2013
Report Publication Announcement
2013-01-14 English
Hinweis auf Jahresfinanzbericht vom 01.01.2012 bis zum 31.12.2012
Report Publication Announcement
2013-01-14 German
Datum:14.01.2013
Report Publication Announcement
2013-01-14 German
Press Release: 4SC obtains key patent for anti-cancer compound resminostat in Europe
Regulatory Filings
2013-01-08 English